.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CA04_Vinorelbine.Vinorelbine_1 .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CA04_Vinorelbine.Vinorelbine_1| name: | Vinorelbine_1 |
| ATC code: | L01CA04_1 | route: | oral |
| n-compartments | 2 |
Vinorelbine is a semi-synthetic vinca alkaloid antineoplastic agent primarily used for treatment of non-small cell lung cancer and metastatic breast cancer.
Oral vinorelbine pharmacokinetics in adult cancer patients; values based on clinical studies with oral administration. Bioavailability is less than intravenous.
Pétain, A, et al., & Ferré, P (2019). Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis. Cancer chemotherapy and pharmacology 84(2) 373–382. DOI:10.1007/s00280-019-03872-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31134323
Hamimed, M, et al., & Leblond, P (2022). Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low-grade glioma. British journal of clinical pharmacology 88(5) 2096–2117. DOI:10.1111/bcp.15131 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34709655
Hamimed, M, et al., & Ciccolini, J (2022). Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis. Cancer chemotherapy and pharmacology 90(1) 29–44. DOI:10.1007/s00280-022-04446-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/35751658